USPTO serial 99361536
DIRECT BIOLOGICS
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- DIGAN, MATTHEW M
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with DIRECT BIOLOGICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*
Plus Government fees of $450
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Aaron D. Hendelman
Aaron D. Hendelman WILSON SONSINI GOODRICH & ROSATI650 Page Mill RoadPalo Alto, CA 94304United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Exosomes for use in the manufacture of cosmetics and pharmaceuticals | ACTIVE | — |
| 005 | Pharmaceutical and therapeutic preparations for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; pharmaceutical and therapeutic preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders | ACTIVE | — |
| 044 | Gene therapy; cell therapy; services in the field of regenerative medicine; diagnosing the need for, and administering, regenerative medicine; regenerative medicine services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Direct Biologics, LLC
- Other trademarks owned by Direct Biologics, LLC
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named DIRECT BIOLOGICS
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 28, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 2, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 2, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 27, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 8, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 23, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 23, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 23, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 21, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 19, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 16, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 27, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 27, 2025 | NWAP | NEW APPLICATION ENTERED | — |